CDK9 inhibition with AZD4573 in DLBCL

We report the effects of CDK9 inhibition (AZD4573) on the epigenetic landscape in Diffuse Large B-cell Lymphoma (DLBCL). This study utilized the Assay for Transposase-Accessible Chromatin with high-throughput sequencing (ATAC-seq) to assess genome-wide chromatin accessibility in two DLBCL cell lines, OCI-LY3 and VAL, treated with AZD4573 (30 nM) at 0, 3, and 8 hours. We found that CDK9 inhibition led to gain and loss of accessible chromatin genome-wide, with enrichment of CTCF/BORIS motifs in decreased accesibility regions. Overall design: Two DLBCL cell lines, OCI-LY3 (GC-DLBCL) and VAL (ABC-DLBCL), were treated with AZD4573 (30 nM) for 0, 3, and 8 hours then were subjected to ATAC-sequencing. Each condition had two replicates prepared with an input of 50,000 cells using the standard ATAC-seq methodology, and two samples prepared with 5,000 cells using the fast-ATAC-seq method. Samples with different input number from the same condition merged together well using PCA.